Research and development progress in cancer therapeutics is marked by innovative strategies targeting tumor biology and microenvironments. Genentech describes inhibitors targeting KRAS G12D mutations, a key oncogenic driver. Sunrock Biopharma and Escugen collaborate to develop a CCR9-directed antibody-drug conjugate for solid tumors. MD Anderson uncovers B-cell lymphoma microenvironment subtypes predictive of CD19 CAR T cell therapy outcomes. Agenus and Noetik’s AI platform aims to elevate immunotherapy responders by modeling tumor-immune interactions at multiple molecular layers.